Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- ALNOV.PA
- Price
- 0.52
- Stock movement up
- +0.06 (11.96%)
- Company name
- Novacyt
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Medical Devices
- Market cap
- 36.37M
- Ent value
- -
- Price/Sales
- 4.39
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 28.71%
- 1 year return
- -22.09%
- 3 year return
- -35.62%
- 5 year return
- -34.74%
- 10 year return
- -20.73%
Last updated: 2025-04-09
DIVIDENDS
ALNOV.PA does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 4.39 |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 70.63M |
| EPS (TTM) | - |
| FCF per share (TTM) | - |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 8.29M |
| Gross profit (TTM) | -935.81K |
| Operating income (TTM) | -11.38M |
| Net income (TTM) | -20.07M |
| EPS (TTM) | - |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | -11.29% |
| Operating margin (TTM) | -137.29% |
| Profit margin (TTM) | -242.04% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 44.05M |
| Net receivables | 14.40M |
| Total current assets | 86.45M |
| Goodwill | 21.45M |
| Intangible assets | 10.23M |
| Property, plant and equipment | 34.65M |
| Total assets | 133.81M |
| Accounts payable | 2.31M |
| Short/Current long term debt | 13.70M |
| Total current liabilities | 29.57M |
| Total liabilities | 46.57M |
| Shareholder's equity | 87.24M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -28.39M |
| Capital expenditures (TTM) | 1.12M |
| Free cash flow (TTM) | -9.82M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | - |
| Return on Invested Capital | - |
| Cash Return on Invested Capital | - |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.52 |
| Daily high | 0.53 |
| Daily low | 0.45 |
| Daily Volume | 742K |
| All-time high | 13.24 |
| 1y analyst estimate | 4.12 |
| Beta | -1.77 |
| EPS (TTM) | - |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| ALNOV.PA | S&P500 | |
| Current price drop from All-time high | -96.11% | -19.00% |
| Highest price drop | -99.29% | -56.47% |
| Date of highest drop | 25 Oct 2019 | 9 Mar 2009 |
| Avg drop from high | -71.35% | -11.07% |
| Avg time to new high | 264 days | 12 days |
| Max time to new high | 2004 days | 1805 days |
COMPANY DETAILS
Marketcap
36.37M
Marketcap category
Small-cap
Description
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, and Yourgene Health segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The company was incorporated in 2006 and is based in Le Vésinet, France.
Employees
240
Website
Investor relations
-
SEC filings
CEO
Country
France
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Revenue growth driven by Yourgene acquisition, cost savings ahead of schedule, but challenges remain with increased OpEx and net loss.
September 27, 2024
A British biotech business that produced thousands of Covid-19 tests during the pandemic has agreed to pay the Government £5m to settle claims they were defective.
June 11, 2024
It agreed the settlement for ‘all claims and counterclaims’ related to recent High Court proceedings over allegations the tests were defective.
June 11, 2024